Full Press Release Details
Ultragenyx Announces License of Intellectual Property Related to the Treatment of Huntington's Disease With Triheptanoin.
RARE
Ultragenyx Announces License of Intellectual Property Related to the Treatment of Huntington's Disease With Triheptanoin
Key Takeaway: Ultragenyx Announces License of Intellectual Property Related to the Treatment of Huntington's Disease With Triheptanoin
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+43%
120-day peak, hindsight
Typical move
2.9%
average across 6 past catalysts
Cash runway
~13 mo
Low dilution risk
Lead asset
BPS804
Phase 2 · Hypophosphatasia